Cost-Effectiveness of a National Opportunistic Screening Program for Atrial Fibrillation in Ireland

被引:22
作者
Moran, Patrick S. [1 ,2 ]
Teljeur, Conor [2 ,3 ]
Harrington, Patricia [2 ]
Smith, Susan M. [4 ]
Smyth, Breda [5 ]
Harbison, Joseph [6 ]
Normand, Charles [7 ]
Ryan, Mairin [2 ,8 ]
机构
[1] Trinity Coll Dublin, Sch Med, Hlth Policy & Management, Foster Pl, Dublin 2, Ireland
[2] Hlth Informat & Qual Author, Hlth Technol Assessment, Dublin, Ireland
[3] Trinity Coll Dublin, Dept Publ Hlth & Primary Care, Dublin, Ireland
[4] Royal Coll Surgeons Ireland, Dept Gen Practice, Dublin, Ireland
[5] Merlin Pk Univ Hosp, Dept Publ Hlth, Hlth Serv Execut, Galway, Ireland
[6] St James Hosp, Trinity Coll Dublin, Hlth Sci Ctr, Dublin, Ireland
[7] Trinity Coll Dublin, Sch Med, Dept Hlth Policy & Management, Dublin, Ireland
[8] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Dublin, Ireland
关键词
atrial fibrillation; pulse palpation; screening; stroke; QUALITY-OF-LIFE; LONG-TERM SURVIVAL; STROKE PREVENTION; ISCHEMIC-STROKE; INTRACEREBRAL HEMORRHAGE; ANTITHROMBOTIC TREATMENT; ORAL ANTICOAGULANTS; GENERAL-POPULATION; SYSTEMIC EMBOLISM; RHYTHM-MANAGEMENT;
D O I
10.1016/j.jval.2016.07.007
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: To evaluate the cost-effectiveness of a national atrial fibrillation screening program in Ireland involving annual opportunistic pulse palpation of all those older than 65 years during general practitioner consultations, with an electrocardiogram being performed if an irregular pulse is detected. Methods: A probabilistic Markov model was used to simulate costs and clinical outcomes in a hypothetical cohort of men and women with and without screening over the course of 25 years, using a societal perspective. Results: Screening was associated with an incremental cost-effectiveness ratio of 23,004/quality-adjusted life-year compared with routine care. Nevertheless, if the relative risk of stroke and systematic embolism in screen-detected patients is more than 12% lower than that in patients with atrial fibrillation identified through routine practice, then screening would not be considered cost-effective at a willingness-to-pay threshold of 45,000/quality-adjusted life-year. An analysis comparing alternative combinations of start age and screening interval found that less frequent screening with a later start age may be more cost-effective than an annual screening from age 65 years. Conclusions: Annual opportunistic screening of men and women aged 65 years and older in primary care in Ireland is likely to be cost-effective using conventional willingness-to-pay thresholds, assuming that those detected through screening have a comparable stroke risk profile as those detected through routine practice. Raising the start age of screening or increasing the screening interval may improve the cost-effectiveness of a prospective screening program.
引用
收藏
页码:985 / 995
页数:11
相关论文
共 50 条
  • [31] Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation
    Kansal, Anuraag R.
    Zheng, Ying
    Pokora, Tiffany
    Sorensen, Sonja V.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (02) : 225 - 237
  • [32] Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
    Lip, Gregory Y. H.
    Lanitis, Tereza
    Kongnakorn, Thitima
    Phatak, Hemant
    Chalkiadaki, Corina
    Liu, Xianchen
    Kuznik, Andreas
    Lawrence, Jack
    Dorian, Paul
    CLINICAL THERAPEUTICS, 2015, 37 (11) : 2476 - 2488
  • [33] Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation
    Mensch, Alexander
    Stock, Stephanie
    Stollenwerk, Bjoern
    Mueller, Dirk
    PHARMACOECONOMICS, 2015, 33 (03) : 271 - 283
  • [34] A Cost-Effectiveness Analysis of Biomarkers for Risk Prediction in Atrial Fibrillation
    Nakhle, Gisele
    Tardif, Jean-Claude
    Roy, Denis
    Rivard, Lena
    Samuel, Michelle
    Dubois, Anick
    LeLorier, Jacques
    MOLECULAR DIAGNOSIS & THERAPY, 2023, 27 (03) : 383 - 394
  • [35] Cost-effectiveness of screening for atrial fibrillation in a single primary care center at a 3-year follow-up
    Ghazal, Faris
    Aronsson, Mattias
    Al-Khalili, Faris
    Rosenqvist, Marten
    Levin, Lars-Ake
    SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2022, 56 (01) : 35 - 41
  • [36] Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies The SEARCH-AF study
    Lowres, Nicole
    Neubeck, Lis
    Salkeld, Glenn
    Krass, Ines
    McLachlan, Andrew J.
    Redfern, Julie
    Bennett, Alexandra A.
    Briffa, Tom
    Bauman, Adrian
    Martinez, Carlos
    Wallenhorst, Christopher
    Lau, Jerrett K.
    Brieger, David B.
    Sy, Raymond W.
    Ben Freedman, S.
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (06) : 1167 - 1176
  • [37] Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
    Hallinen, Taru
    Soini, Erkki J.
    Linna, Miika
    Saarni, Samuli I.
    SPRINGERPLUS, 2016, 5
  • [38] Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran
    Rezaei, Satar
    Bavandpour, Maryam
    Mobinizadeh, Mohammadreza
    Daroudi, Rajabali
    BMC RESEARCH NOTES, 2024, 17 (01)
  • [39] Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain
    Gonzalez-Juanatey, Jose R.
    Alvarez-Sabin, Jose
    Lobos, Jose M.
    Martinez-Rubio, Antoni
    Reverter, Joan C.
    Oyagueez, Itziar
    Gonzalez-Rojas, Nuria
    Becerra, Virginia
    REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (10): : 901 - 910
  • [40] Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
    Chang, Chia-Hsien
    Yang, Yea-Huei Kao
    Chen, Jyh-Hong
    Lin, Li-Jen
    THROMBOSIS RESEARCH, 2014, 133 (05) : 782 - 789